logo-loader
viewOpen Orphan PLC

Open Orphan launches “best-in-class" coronavirus testing service

Chairman Cathal Friel said “We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees”

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) has announced the launch of hVIVO's COVID Clear Test, its antibody testing service, following the successful completion of installation, testing and training for the coronavirus (COVID-19) test,

The service will be offered to large employer groups and partners including GP networks, nursing care businesses, health clinics and private hospitals.

Samples will be tested in the company's London lab with results returned within 48 hours.

Open Orphan subsidiary hVIVO is using the Quotient MosaiQ system and MosaiQ COVID-19 Antibody Microarray, which it said has the “best-in-class COVID-19 antibody testing performance”.

In a statement, Open Orpan chairman Cathal Friel said: "hVIVO is a world-class company with best in class scientists and facilities. We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees.”

Quick facts: Open Orphan PLC

Price: 11.49999 GBX

AIM:ORPH
Market: AIM
Market Cap: £76.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC targeting Q3 for profitability as it expands range of pharma...

Proactive Research analyst Emma Ulker says Open Orphan PLC's (LON:ORPH) full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period...

1 week, 5 days ago

2 min read